Dynamics of β-Amyloid Reductions in Brain, Cerebrospinal Fluid, and Plasma of β-Amyloid Precursor Protein Transgenic Mice Treated with a γ-Secretase Inhibitor

Donna M. Barten(Vertex Pharmaceuticals (United States)), Valerie Guss(NeuroGenetic Pharmaceuticals (United States)), Jason A. Corsa(Johnson & Johnson (United States)), Alice Loo(Intra Cellular Therapies (United States)), Steven Hansel(Johnson & Johnson (United States)), Ming Zheng(Johnson & Johnson (United States)), B. Muñoz(NeuroGenetic Pharmaceuticals (United States)), K. Srinivasan(Vertex Pharmaceuticals (United States)), Binghe Wang(Pfizer (United States)), Barbara Robertson(Vertex Pharmaceuticals (United States)), Craig Polson(Vertex Pharmaceuticals (United States)), Jue Wang(Pfizer (United States)), Susan B. Roberts(Bristol-Myers Squibb (United States)), Joseph P. Hendrick(Vertex Pharmaceuticals (United States)), Jeffrey J. Anderson(Pfizer (United States)), James Loy(Bristol-Myers Squibb (United States)), Ross M. Denton(Merck & Co., Inc., Rahway, NJ, USA (United States)), Todd A. Verdoorn(NeuroGenetic Pharmaceuticals (United States)), David W. Smith(Pfizer (United States)), Kevin M. Felsenstein(Vertex Pharmaceuticals (United States))
Journal of Pharmacology and Experimental Therapeutics
January 15, 2005
Cited by 159

Abstract


Related Papers

No related papers found

Powered by citation graph analysis